XBiotech sinks on Phase III colorectal data

XBiotech Inc. (NASDAQ:XBIT) fell $8.10 (33%) to $16.80 on Tuesday after reporting results from a Phase

Read the full 167 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE